~~<i id='EFFF6C1E10'><strike id='EFFF6C1E10'><tt id='EFFF6C1E10'><pre id='EFFF6C1E10'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：entertainment 2025-09-28 17:43:44 - browse：38

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Moderna hits safety problems in bold bid to reinvent medicine

explore

Wikipedia

leisure time

hotspot

focus

explore

AdamFeuerstein,upperleft,moderatedapanelwith,clockwise,DavidChangofAllogeneTherapeutics,RachelHaurwi

WSS

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

A new House health package & hospitals’ new site

Boeing's 1st astronaut flight bumped into next year, more repairs needed

The UK government moves asylum

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

entertainment

focus

explore

What does generative AI mean for health care? We asked experts

Stem cell treatment guidelines are released by FDA

Hollywood unions extend contract negotiations for actors

Amazon on where the company's health care bets are headed next

Malaria cases in Florida and Texas: Here’s what you need to know

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Illinois to ban advertising for guns allegedly marketed to kids and militants

Walensky prepares to leave CDC — and Congress — behind

Democratic lawmaker calls for 'well

Wikipedia

Why Novartis is changing the name of its research labs

At least 12 people were injured in a blast at a port in northwest Turkey

House transparency, PBM reform bill gains bipartisan support

How to protect patients from sexual assault

Snackable artificial intelligence, expert AI, and the pharma industry

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

leisure time

hotspot

focus

explore